Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co. Ltd. currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These cases are assigned to 3 distinct examiners, including REDWOOD, CHRISTOPHER EVAN, who is the busiest examiner for the portfolio. The matters are distributed across 2 distinct art units.
The presence of 3 pending office actions and 3 distinct examiners indicates that each case is being reviewed by a different individual. REDWOOD, CHRISTOPHER EVAN is responsible for 1 pending case, which shows that the workload is spread across the assigned staff. This structure requires the company to adapt to 3 different examination styles simultaneously.
Although there are 3 distinct examiners, the concentration within 2 distinct art units may provide some technical consistency across the Biotechnology & Pharmaceuticals filings. Since REDWOOD, CHRISTOPHER EVAN handles 1 pending case, the practitioner must maintain separate communication channels for each matter. The prosecution strategy should focus on the specific requirements of the 2 distinct art units while addressing the unique feedback from each examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
| FUBARA, BLESSING M | 1 | 62.2% | +34.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682111 | APPLICATION OF STEROID COMPOUND IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING EYE FLOATERS | ARCORIA, PAUL JOSEPH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577690 | COMPOSITION CONTAINING LOXOPROFEN SODIUM | FUBARA, BLESSING M | 63d |
| 18857012 | USE OF STEROID COMPOUND IN PREPARING DRUGS FOR PREVENTING AND/OR TREATING PRESBYOPIA | REDWOOD, CHRISTOPHER EVAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577690 | COMPOSITION CONTAINING LOXOPROFEN SODIUM | FUBARA, BLESSING M | 63d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18857012 | USE OF STEROID COMPOUND IN PREPARING DRUGS FOR PREVENTING AND/OR TREATING PRESBYOPIA | REDWOOD, CHRISTOPHER EVAN | — | §102§103Other | Non-Final OA | — | Pending | Oct 15, 2024 |
| 18682111 | APPLICATION OF STEROID COMPOUND IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING EYE FLOATERS | ARCORIA, PAUL JOSEPH | 1621 | §103 | Final Rejection | — | Pending | Feb 07, 2024 |
| 18577690 | COMPOSITION CONTAINING LOXOPROFEN SODIUM | FUBARA, BLESSING M | 1613 | §103§112 | Non-Final OA | 63d | Pending | Jan 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOcusun Ophthalmic Pharmaceutical (Guangzhou) Co. Ltd. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Christopher Evan Redwood has the most, with 1 of Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
